Cargando…
Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
Glioblastoma is the most common primary brain tumor in the adult and carries a poor prognosis with a median survival of only 14 months. Patients with glioblastoma are followed with MRI scans, but this technique has several limitations including low specificity to differentiate between tumor and trea...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009441/ https://www.ncbi.nlm.nih.gov/pubmed/24809021 http://dx.doi.org/10.3389/fonc.2014.00090 |